HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jenner, P. Search for Related Content PubMed PubMed Citation Articles by Jenner, P.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

A novel dopamine agonist for the transdermal treatment of Parkinson’s disease

From the Neurodegenerative Diseases Research Centre, Guy’s, King’s and St Thomas’ School of Biomedical Sciences, King’s College, London, United Kingdom.

Address correspondence to Dr. Peter Jenner, NDRG,GKT School of Biomedical Sciences, King’s College, London SE1 1UL,UK; e-mail: peter.jenner{at}kcl.ac.uk

Rotigotine is a non-ergot, enantio-selective, D3/D2/D1 dopamine (DA) agonist drug that is effective in classical models of Parkinson’s disease (PD), including the reserpinised mouse, the 6-hydroxydopamine-lesioned rat, and the MPTP-treated primate. It is active after oral administration but shows high clearance and a relatively short duration of effect. However, rotigotine is also effective after transdermal application in 6-hydroxydopamine-lesioned rats and MPTP-treated monkeys, in both of which the duration of effect is markedly enhanced. The pharmacologic properties of rotigotine suggest that it has the characteristics necessary to form the basis of a transdermal treatment for the control of motor symptoms of PD.

Publication of this supplement was supported by an educational grant from Schwarz Pharma. The sponsor has provided P.J. with the following support: an honorarium for his participation in this project, honoraria during his career, and grant support.

This article has been cited by other articles:

				M. Y Splinter Rotigotine: Transdermal Dopamine Agonist Treatment of Parkinson's Disease and Restless Legs Syndrome Ann. Pharmacother., February 1, 2007; 41(2): 285 - 295. [Abstract] [Full Text] [PDF]

				R. F. Pfeiffer A promising new technology for Parkinson's disease Neurology, July 26, 2005; 65(2_suppl_1): S6 - S10. [Full Text]